Sign in with Google. Opens in new tab
BCLI: Receives Regulatory Clearance to Initiate Phase 3b ALS Trial
On May 19, 2025, BrainStorm Cell Therapeutics, Inc. (BCLI) announced that the U.S. Food and Drug Administration (FDA) has cleared the company to...
What is covered in the Full Insight:
- FDA Clearance for Phase 3b ALS Trial
- Details of the Phase 3b ENDURANCE Trial
- Comparison with Previous Trials
- Financial Overview and Estimates
- Outlook and Risk Assessment
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 10-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Nikkei 225 Index Rebalance: Rohm (6963) To Replace NTT Data Group (9613)
- Krungthai Card (KTC TB): Buying Opportunity After Margin Call
- NVIDIA (NVDA US) At All-Time High Acquires CentML: Weekly Tactical Outlook (June 30 – July 4)
- Zijin Mining (2899 HK): Fair Value Still 25% Higher Despite IPO Discount Risks
- Quiddity Leaderboard F100/F250 Sep25 Results: Methodology Change Could Result in a Surprise Addition
Top Unpaywalled Insights
More »- [IO Technicals 2025/26] Bearish Momentum Intensifies
- "The Data Bottleneck in Quant Finance — and How to Break It" With David Forino, CTO of Quanted
- The New OS for Quant Finance: OpenBB, AI Agents & the Death of Legacy Terminals | New Barbarians ...
- Curator's Cut: Building Materials Moves, Benchmarking Gold Miners & Semaglutide in India and Japan
- Overview# 29- The Hard-Asset Reset: Buying the Pullback in Commodities
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Loading...
x